Eculizumab versus rituximab in generalised myasthenia gravis

OBJECTIVE: Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be considered as therapeutic options for refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelke, Christopher, Schroeter, Christina B, Stascheit, Frauke, Pawlitzki, Marc, Regner-Nelke, Liesa, Huntemann, Niklas, Arat, Ercan, Öztürk, Menekse, Melzer, Nico, Mergenthaler, Philipp, Gassa, Asmae, Stetefeld, Henning, Schroeter, Michael, Berger, Benjamin, Totzeck, Andreas, Hagenacker, Tim, Schreiber, Stefanie, Vielhaber, Stefan, Hartung, Hans-Peter, Meisel, Andreas, Wiendl, Heinz, Meuth, Sven G, Ruck, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Neuromuscular
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016243/
https://www.ncbi.nlm.nih.gov/pubmed/35246490
http://dx.doi.org/10.1136/jnnp-2021-328665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016243/
https://www.ncbi.nlm.nih.gov/pubmed/35246490
http://dx.doi.org/10.1136/jnnp-2021-328665

Ejemplares similares